Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

NCT02358044 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Sofosbuvir
BIOLOGICAL: PegIntron
DRUG: Ribavirin
DRUG: Grazoprevir/Elbasvir (100 mg/50 mg) FDC

Sponsor

Merck Sharp & Dohme LLC